Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 5/20 | 0.47 |
| ▸ | CHKA | P35790 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL15821503 | 0.98 | ACHE (0.50) | ALDH1A1KDM4ERAB9AACHECHKA | |
| Bromide SCHEMBL23858158 | 0.84 | CHKA (0.49) | ALDH1A1KDM4ERAB9AACHECHKA | |
| SCHEMBL5307716 | 0.83 | ALDH1A1 (0.53) | ALDH1A1KDM4ERAB9AACHECHKA | |
| Hydrochloric Acid SCHEMBL7307884 | 0.81 | ALDH1A1 (0.56) | ALDH1A1KDM4ERAB9AACHECHKA | |
| SCHEMBL31652036 | 0.81 | ACHE (0.48) | ALDH1A1KDM4ERAB9AACHECHKA | |
| SCHEMBL22674284 | 0.80 | NPC1 (0.38) | ALDH1A1KDM4ERAB9AACHECHKA | |
| SCHEMBL25848023 | 0.79 | LMNA (0.47) | ALDH1A1KDM4ERAB9AACHECHKA | |
| SCHEMBL28927098 | 0.79 | ACHE (0.51) | ALDH1A1KDM4ERAB9AACHECHKA | |
| Hydrochloric Acid SCHEMBL10670016 | 0.76 | ALDH1A1 (0.50) | ALDH1A1KDM4ERAB9AACHECHKA | |
| SCHEMBL15836427 | 0.76 | ALDH1A1 (0.46) | ALDH1A1KDM4ERAB9AACHECHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9481679-B2 | Process for the preparation of tofacitinib and intermediates thereof | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-11-01 | — | — | US | disclosed |
| US-20150322072-A1 | PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2015-11-12 | — | — | US | disclosed |
| WO-2014097150-A1 | PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322072-A1 | PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES THEREOF | JAK3, JAK2, JAK1 | ALDH1A1 3248/4885KDM4E 819/4885RAB9A 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.